SCHEDULE 13G: Armistice Capital and Steven Boyd Disclose 5.91% Stake in Alto Neuroscience

Armistice Capital, LLC and Steven Boyd have jointly disclosed a beneficial ownership of 1,600,000 shares, representing 5.91% of Alto Neuroscience, Inc.'s common stock.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as the "Reporting Persons," have filed a Schedule 13G indicating beneficial ownership in Alto Neuroscience, Inc.
• The filing reports that the Reporting Persons beneficially own an aggregate of 1,600,000 shares of Alto Neuroscience, Inc.'s Common Stock.
• This ownership represents 5.91% of the issuer's outstanding Common Stock.
• The percentage is calculated based on 27,072,129 shares outstanding as of March 17, 2025, as reported in Alto Neuroscience's Form 10-Q filed on March 20, 2025.
• Armistice Capital, LLC, a Delaware entity, acts as the investment manager for Armistice Capital Master Fund Ltd., the direct holder of the shares, and exercises voting and investment power.
• Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC and is deemed to beneficially own the securities held by the Master Fund.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The filing of a Schedule 13G indicates a significant stake by an institutional investor, which can be viewed as a positive signal of confidence in the company's prospects, although it does not provide operational or financial performance details.

Positives

• The disclosure of a significant stake by an institutional investor like Armistice Capital and its managing member, Steven Boyd, can be interpreted as a vote of confidence in Alto Neuroscience, Inc.

Negatives

• NA

Risks

• NA

Future Outlook

NA

Management Comments

• Steven Boyd, as Managing Member of Armistice Capital, LLC, certified that the securities were acquired and are held in the ordinary course of business and not for the purpose or with the effect of changing or influencing the control of the issuer.

Industry Context

This Schedule 13G filing indicates a significant passive investment by an institutional fund and its principal in a publicly traded biotechnology or pharmaceutical company (Alto Neuroscience, Inc.). Such filings are standard disclosures required when an entity or individual acquires beneficial ownership of more than 5% of a company's voting class of securities, signaling a notable position taken by a professional investor.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake may influence investor sentiment and potentially the stock price, signaling confidence in the company.

Next Steps

• The Reporting Persons will be required to file amendments to this Schedule 13G if there are material changes to their beneficial ownership, such as an increase or decrease of 1% or more, or if their intent changes from passive investment to influencing control.

Key Dates

Keywords

Alto Neuroscience, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Equity Stake